ATRC

AtriCure Inc

Add to Watchlist

Advanced Chart

31.500

+1.33(4.408%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

31.570

Open

30.450

VWAP

31.10

Vol

589.27K

Mkt Cap

1.56B

Low

30.410

Amount

18.33M

EV/EBITDA(TTM)

Total Shares

48.38M

1.53B

EV/OCF(TTM)

68.92

P/S(TTM)

3.09

AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

139.62M

+12.35%

-0.060

-24.5%

129.58M

+11.79%

-0.146

-14.14%

130.26M

+12.03%

-0.163

-4.31%

Estimates Revision

The market is revising No Change the revenue expectations for AtriCure, Inc. (ATRC) for FY2025, with the revenue forecasts being adjusted by -0% over the past three months. During the same period, the stock price has changed by -6.44%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-10.63%

In Past 3 Month

Stock Price

Go Down

-6.44%

In Past 3 Month

8 Analyst Rating

59.94% Upside

Wall Street analysts forecast ATRC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRC is 50.38 USD with a low forecast of 40.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

59.94% Upside

Current: 31.500

Low

40.00

Averages

50.38

High

60.00

59.94% Upside

Current: 31.500

Low

40.00

Averages

50.38

High

60.00

Citizens Capital Markets

Daniel Stauder

Buy

Reiterates

$60

2025-04-02

Reason

Citizens Capital Markets

Daniel Stauder

Price Target

$60

2025-04-02

Reiterates

Buy

Reason

Canaccord Genuity

William Plovanic

Strong Buy

Maintains

$66 → $52

2025-03-28

Reason

Canaccord Genuity

William Plovanic

Price Target

$66 → $52

2025-03-28

Maintains

Strong Buy

Reason

Canaccord lowered the firm's price target on AtriCure to $52 from $66 and keeps a Buy rating on the shares. The firm updated its model folloing the company's Investor Day that both reiterated its 2025 guidance and provided an aspirational LRP that included three-year objectives as well as targets for 2030.

Needham

Mike Matson

Strong Buy

Reiterates

$51

2025-03-27

Reason

Needham

Mike Matson

Price Target

$51

2025-03-27

Reiterates

Strong Buy

Reason

JP Morgan

Lilia-Celine Lozada

Buy

Maintains

$51 → $46

2025-03-27

Reason

JP Morgan

Lilia-Celine Lozada

Price Target

$51 → $46

2025-03-27

Maintains

Buy

Reason

Needham

Mike Matson

Strong Buy

Reiterates

$51

2025-03-21

Reason

Needham

Mike Matson

Price Target

$51

2025-03-21

Reiterates

Strong Buy

Reason

Oppenheimer

Suraj Kalia

Buy

Maintains

$36 → $45

2025-02-13

Reason

Oppenheimer

Suraj Kalia

Price Target

$36 → $45

2025-02-13

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for AtriCure Inc (ATRC.O) is -58.70, compared to its 5-year average forward P/E of -49.89. For a more detailed relative valuation and DCF analysis to assess AtriCure Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-49.89

Current PE

-58.70

Overvalued PE

-37.42

Undervalued PE

-62.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

1172.58

Current EV/EBITDA

32.64

Overvalued EV/EBITDA

8466.05

Undervalued EV/EBITDA

-6120.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

6.25

Current PS

2.83

Overvalued PS

9.47

Undervalued PS

3.04